vs
Live Oak Bancshares, Inc.（LOB）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是Live Oak Bancshares, Inc.的1.5倍（$219.9M vs $145.5M），Live Oak Bancshares, Inc.净利率更高（19.2% vs -1.0%，领先20.2%），Live Oak Bancshares, Inc.同比增速更快（18.4% vs 2.0%），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 7.7%）
Live Oak Bancshares, Inc.是一家美国金融控股公司，旗下子公司Live Oak Bank总部位于北卡罗来纳州威尔明顿，业务覆盖美国全部50个州，专注为小企业主提供金融服务，2022年按放贷金额计是美国SBA 7(a)贷款项目的头部放贷机构。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
LOB vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.5倍
$145.5M
营收增速更快
LOB
高出16.4%
2.0%
净利率更高
LOB
高出20.2%
-1.0%
两年增速更快
OFIX
近两年复合增速
7.7%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $145.5M | $219.9M |
| 净利润 | $27.9M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | — | 0.2% |
| 净利率 | 19.2% | -1.0% |
| 营收同比 | 18.4% | 2.0% |
| 净利润同比 | 187.6% | 92.4% |
| 每股收益（稀释后） | $0.60 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LOBOFIX
| Q1 26 | $145.5M | — | ||
| Q4 25 | $161.9M | $219.9M | ||
| Q3 25 | $146.1M | $205.6M | ||
| Q2 25 | $143.7M | $203.1M | ||
| Q1 25 | $126.1M | $193.6M | ||
| Q4 24 | $116.9M | $215.7M | ||
| Q3 24 | $129.9M | $196.6M | ||
| Q2 24 | $125.5M | $198.6M |
净利润LOBOFIX
| Q1 26 | $27.9M | — | ||
| Q4 25 | $46.2M | $-2.2M | ||
| Q3 25 | $26.5M | $-22.8M | ||
| Q2 25 | $23.4M | $-14.1M | ||
| Q1 25 | $9.7M | $-53.1M | ||
| Q4 24 | $9.9M | $-29.1M | ||
| Q3 24 | $13.0M | $-27.4M | ||
| Q2 24 | $27.0M | $-33.4M |
毛利率LOBOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% |
营业利润率LOBOFIX
| Q1 26 | — | — | ||
| Q4 25 | 38.2% | 0.2% | ||
| Q3 25 | 25.0% | -8.3% | ||
| Q2 25 | 21.7% | -7.9% | ||
| Q1 25 | 10.4% | -25.2% | ||
| Q4 24 | 11.3% | -5.3% | ||
| Q3 24 | 13.7% | -9.6% | ||
| Q2 24 | 28.7% | -12.5% |
净利率LOBOFIX
| Q1 26 | 19.2% | — | ||
| Q4 25 | 28.5% | -1.0% | ||
| Q3 25 | 18.1% | -11.1% | ||
| Q2 25 | 16.3% | -6.9% | ||
| Q1 25 | 7.7% | -27.4% | ||
| Q4 24 | 8.5% | -13.5% | ||
| Q3 24 | 10.0% | -13.9% | ||
| Q2 24 | 21.5% | -16.8% |
每股收益（稀释后）LOBOFIX
| Q1 26 | $0.60 | — | ||
| Q4 25 | $0.96 | $-0.05 | ||
| Q3 25 | $0.55 | $-0.57 | ||
| Q2 25 | $0.51 | $-0.36 | ||
| Q1 25 | $0.21 | $-1.35 | ||
| Q4 24 | $0.22 | $-0.76 | ||
| Q3 24 | $0.28 | $-0.71 | ||
| Q2 24 | $0.59 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.3B | $450.0M |
| 总资产 | $15.3B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LOBOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | $82.0M | ||
| Q3 25 | — | $62.9M | ||
| Q2 25 | — | $65.6M | ||
| Q1 25 | — | $58.0M | ||
| Q4 24 | — | $83.2M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $26.4M |
总债务LOBOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M |
股东权益LOBOFIX
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.2B | $450.0M | ||
| Q3 25 | $1.2B | $442.5M | ||
| Q2 25 | $1.1B | $458.3M | ||
| Q1 25 | $1.0B | $458.3M | ||
| Q4 24 | $999.0M | $503.1M | ||
| Q3 24 | $1.0B | $525.9M | ||
| Q2 24 | $961.0M | $546.0M |
总资产LOBOFIX
| Q1 26 | $15.3B | — | ||
| Q4 25 | $15.1B | $850.6M | ||
| Q3 25 | $14.7B | $832.6M | ||
| Q2 25 | $13.8B | $837.2M | ||
| Q1 25 | $13.6B | $823.1M | ||
| Q4 24 | $12.9B | $893.3M | ||
| Q3 24 | $12.6B | $867.9M | ||
| Q2 24 | $11.9B | $882.0M |
负债/权益比LOBOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | — | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流LOBOFIX
| Q1 26 | — | — | ||
| Q4 25 | $158.2M | $27.7M | ||
| Q3 25 | $62.3M | $12.4M | ||
| Q2 25 | $49.2M | $11.6M | ||
| Q1 25 | $-33.0M | $-18.4M | ||
| Q4 24 | $156.8M | $23.7M | ||
| Q3 24 | $47.4M | $11.7M | ||
| Q2 24 | $29.5M | $9.0M |
自由现金流LOBOFIX
| Q1 26 | — | — | ||
| Q4 25 | $143.5M | $16.8M | ||
| Q3 25 | $60.6M | $2.5M | ||
| Q2 25 | $47.8M | $4.5M | ||
| Q1 25 | $-35.3M | $-25.1M | ||
| Q4 24 | $107.5M | $15.2M | ||
| Q3 24 | $41.0M | $6.3M | ||
| Q2 24 | $12.3M | $-360.0K |
自由现金流率LOBOFIX
| Q1 26 | — | — | ||
| Q4 25 | 88.6% | 7.6% | ||
| Q3 25 | 41.4% | 1.2% | ||
| Q2 25 | 33.3% | 2.2% | ||
| Q1 25 | -28.0% | -13.0% | ||
| Q4 24 | 91.9% | 7.0% | ||
| Q3 24 | 31.6% | 3.2% | ||
| Q2 24 | 9.8% | -0.2% |
资本支出强度LOBOFIX
| Q1 26 | — | — | ||
| Q4 25 | 9.1% | 4.9% | ||
| Q3 25 | 1.2% | 4.8% | ||
| Q2 25 | 1.0% | 3.5% | ||
| Q1 25 | 1.8% | 3.5% | ||
| Q4 24 | 42.2% | 4.0% | ||
| Q3 24 | 4.9% | 2.7% | ||
| Q2 24 | 13.7% | 4.7% |
现金转化率LOBOFIX
| Q1 26 | — | — | ||
| Q4 25 | 3.42× | — | ||
| Q3 25 | 2.35× | — | ||
| Q2 25 | 2.10× | — | ||
| Q1 25 | -3.39× | — | ||
| Q4 24 | 15.84× | — | ||
| Q3 24 | 3.64× | — | ||
| Q2 24 | 1.10× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LOB
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
